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Abstract
Background: Benign hereditary chorea is a rare disorder which is characterized by early onset, non-progressive
choreic movement disturbance, with other hyperkinetic movements and unsteadiness also commonly seen.
Hypothyroidism and lung disease are frequent additional features. The disorder is caused by mutations of the NKX2-1
gene on chromosome 14.
Case presentation: A Norwegian four-generation family with eight affected was identified. All family members
had an early onset movement disorder, starting before one year of age with motor delay and chorea. Learning
difficulties were commonly reported from early school years. The family presented with choreic movements at
rest, but other movements were seen; myoclonus, dystonia, ataxia, stuttering and tics-like movements. All
patients reported unsteadiness and ataxic gait was observed in two patients. Videos are provided in the
supplementary material. Most affected family members had asthma and a subclinical or clinical hypothyroidism.
Sequencing revealed a mutation in the NKX2-1 gene in all eight affected family members.
Conclusions: This is the first Norwegian family with benign hereditary chorea due to a mutation in the NKX2-1 gene,
c.671 T > G (p.Leu224Arg). This family demonstrates well the wide phenotype, including dystonia, myoclonus and ataxia.
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Background
Benign hereditary chorea (BHC, MIM 118700) is an auto-
somal dominant movement disorder, characterized by
early onset choreic movements and often hypotonia and
delayed motor development [1–5]. In addition, other
hyperkinetic movements may be present in up to 50 % of
patients [5–10]. The hyperkinetic movements are typically
aggravated by stress and disappear during sleep. BHC
patients show minimal or no disease progression, and pro-
gressive dementia is not observed [11, 12]. Typically, an
MRI of the brain shows no structural changes. The sever-
ity of symptoms varies widely, even in families with the
same disease-causing mutation [5, 6, 13, 14]. ~Thirty per-
cent of the patients appear to be sporadic in large cohorts
due to reduced penetrance and de-novo deletions [5, 6].
The epidemiology of BHC is uncertain as the disease is rare
and symptoms can be subtle. A prevalence estimate from
Wales was 1 per 500 000, but this was done prior to gen-
etic testing and the prevalence thus remains uncertain [4].
BHC is most often caused by mutations in the NKX2-1
gene on chromosome 14 [15–17], but up to 50 % of the
families initially given a clinical BHC diagnosis tested
negative for mutations in the NKX2-1 gene, however mu-
tations in other genes may be associated with a similar
phenotype, Table 1 [6, 7, 9, 18, 19]. As of today, sixty-one
mutations have been described in the NKX2-1 gene [6].
Genotype-phenotype correlations have not been found,
but a milder phenotype is most often reported in patients
with a missense mutation affecting the terminal regions of
the protein compared to those with large deletions of the
gene [1, 2, 5, 6, 13, 15–17, 20–22]. The gene encodes a
homeodomain-containing transcription factor, TITF-1
(thyroid transcription factor-1), which is essential for the
organogenesis of lung, thyroid and basal ganglia. The
mutations are presumed to be disease causing due to hap-
loinsufficiency [1, 2]. Mutations in the NKX2-1 gene can
also be associated with hypothyroidism and pulmonary
disease as part of the “brain-lung-thyroid syndrome”[23].
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The clinical spectrum in patients with mutations in the
NKX2-1 gene varies from the complete triad of brain-lung-
thyroid syndrome (up to ~50 % of the patients), to brain
and thyroid disease (~30 %), or isolated BHC (~20 %)
which is the mildest expression of the syndrome [5], Fig. 1.
No curative treatment for this disorder is currently avail-
able, but there is one report of improvement in the hyper-
kinetic movements from tetrabenazine in a few patients
who tried the medication [5]. In addition case articles have
reported effect of levodopa [5, 20] and methylphenidate or
haloperidol [24] in a few other subjects.
A large BHC cohort was described in 2012 [5], including
this Norwegian family. The objective of this study is to
provide a detailed description of the clinical data, medica-
tion response, neuropsychological features and videos
from this first Norwegian BHC family.
Case presentation
Methods and patients
During an ongoing study on movement disorders and
hereditary ataxias in Norway [25], this four-generation
family with eight affected subjects was referred to the
department with possible hereditary ataxia, Fig. 2.
Videos were recorded from the examinations for all
affected subjects and reviewed by experienced clinicians.
The Scale for the Assessment and Rating of Ataxia
(SARA-scale) was used to rate ataxia-related symptoms
on a scale from 0 (no ataxia) to 40 (severe ataxia) [26].
Brain MRI scanning, mini-mental state test (MMS)
and neuropsychological tests were performed in four
available affected family members. Due to different ages,
different test panels were used. WISC-IV (<18 years)
and WASI (>18 years) were used for assessment of the
Intelligence Quotient (IQ). Verbal Fluency Test, Stroop
test and California Verbal Learning Test (CVLT) were
performed to assess verbal executive function, executive
functions with inhibition, selective attention, and verbal
learning and memory. Paced Auditory Serial Addition
Test (PASAT) was used to assess attention and working
memory [27–29]. Due to geographical restrictions it was
not possible to test all family members.
Blood samples were collected from all affected and
unaffected family members. DNA was extracted from
blood lymphocytes and sequenced using standard tech-
niques. The sequence data have been described in an
earlier publication [5].
Written informed consent was obtained from all in-
cluded family members in accordance with the ethical
agreement n° 129/04011 of the Regional Ethical Com-
mittee in Norway.
Clinical data
Age of onset was during the first year of life in all sub-
jects and hyperkinetic movements were the first re-
ported symptoms in all. All affected subjects had delayed
motor skills, but 4/8 reached the walking milestone
Table 1 Differential diagnoses for benign hereditary chorea
Diagnosea Gene Genetic cluese Main clinical features
Benign hereditary chorea (BHC) NKX2-1 AD, early onset Hypotonia, chorea, lung and thyroid symptoms
Myoclonus dystonia (DYT11) SGCE AD, maternal imprinting Myoclonus of short duration (<150 ms), dystonia
BHC like disorder ADCY5 AD Paroxysmal choreic/dystonic movements, facial myokymia
Huntington’s diseaseb HTT AD, anticipation Chorea, athetosis, worsen over time, psychiatric symptoms and dementia
Huntington’s disease - like
disorder 1–4c
PRNP, JPH3, TBP AD/AR Chorea, athetosis, worsen over time, psychiatric symptoms and dementia
Other Huntington's - like
disorders
RNF216 AR Cerebellar ataxia, behavioral problems, dementia, white matter lesions,
hypogonadotropic hypogonadism, in some families chorea and athetosis
Ataxia telangiectasia ATM AR Oculomotor apraxia, telangiectasia, dystonia
AOA1 (Ataxia with
oculomotor apraxia 1)
APTX AR Early-onset cerebellar signs, sensory neuropathy, cognitive
decline, and oculomotor deficits
Friedreich ataxia FXN AR Sensory disturbances, spaticity, hyporeflexia, rare presentations
with chorea and myoclonus
Hereditary ataxias
(SCA1,2,3,6,7,17, DRPLA)
ATXN1-3, CACNA1A,
ATXN17, TBN, ATN1
AD Progressive ataxia, cerebellar (and brainstem) atrophy
Glucose transporter
type 1 deficiency
SLC2A1 AD Chorea and often mental retardation associated with a
combination of paroxysmal ataxia, dystonia and/or epilepsy
Neurodegeneration with brain
iron accumulation (NBIA)d
PANK2 AR/X-linked/AD Typical MRI findings, dystonia, progression, cognitive decline
aThere are many acquired conditions mimicking BHC in addition to this list
bIn Huntington’s disease the juvenile forms often present with dystonia or parkinsonism
cHuntington disease like (HDL) 1–4; unknown gene in HDL3 (questioned entity), HDL4 the same as SCA17. HDL1 also known as inherited prion disease
dMutations in ten genes can cause NBIA. Mutations in PANK2 is the most common
eMany of these disorders appear sporadic due to reduced penetrance/age-dependent penetrance, variable expressivity and de-novo mutations
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within normal range. The movement disorder was re-
ported to be stable, but observed to be more prominent
in the youngest generation. All patients reported in-
creased symptoms with stress and two reported some re-
lief in hyperkinetic movements with ethanol
consumption. Learning difficulties in early school age
was reported in 7/8. Only one of the patients had an
academic education. Clinical data are given in Table 2.
The mean age at the time of examination was 36 years
with an average of 33.5 years (range 7–63 years). All sub-
jects had involuntary movements with chorea at the time
of examination. Chorea was the most prominent hyper-
kinetic movement in the three youngest, Additional file 1:
Video 1. The older generations exhibited myoclonus (one
subject), a mixture of dystonia and chorea (three subjects),
Additional file 2: Video 2, and tics, stuttering and dystonia
(one subject). All subjects were unsteady and unable to
walk ten steps in tandem and two subjects had mild gait
ataxia, Additional file 3: Video 3. Saccadic pursuit was
consistently observed in all when tested for slow pursuit.
Hanging reflexes or increased reflexes were seen in 7/8,
Additional file 2: Video 2. Archimedes spiral drawing was
inaccurate in all the affected subjects, illustrated by subject
IV-2, Fig. 3.
No changes in symptoms were observed in the index
patient and the youngest generation at two years follows
up time.
Brain MRI’s were normal in the four scanned subjects.
No short stature, microcephaly, epilepsy, pulmonary
carcinoma or psychiatric disorders were reported or ob-
served in the family.
Levodopa failed to improve the involuntary movements
in II:7 and III:6 (1.5-3 mg/kg/day). Clonazepam (0.5 mg/
day) relieved the hyperkinetic symptoms in III:7 to some
degree, but III:6 observed only side-effects (dizziness and
fatigue). Tetrabenazine was tested in increasing doses in
IV:2 and IV:3 (up to 0.35 mg/kg/day). Side-effects
appeared after a few days and the medication was discon-
tinued after one week with nocturnal bed-wetting for IV:2
and depressive symptoms in IV:3. Topiramate was tried in
two subjects with BMI > 30. They reported some reduc-
tion in involuntary movements, but Topiramate was dis-
continued after one month due to side effects with
depressive symptoms and fatigue in both.
Neuropsychological testing
Neuropsychological test results for four subjects are
shown in Table 2. Verbal IQ was consistently lower than
performance IQ in all. The index subject showed re-
duced working memory and attention in the PASAT
test, scoring 29/60.
Subjects IV:1, IV:2 and IV:3 were tested with WISC-IV
and all showed working memory and processing speed
in the lower range. These three subjects performed in
the lower normal range in verbal memory and verbal flu-
ency, while visual memory and understanding was in the
middle normal range.
All four reported concentration problems, as reflected
in reduced attention and concentration. The most sig-
nificant attention impairment was seen in patient IV:1,
with Stroop results corresponding to the 2nd percentile.
Case description
The index patient was referred to our clinic due to un-
steadiness and clumsiness from early school age. She
wanted a second opinion when she was 34 years old on
her “hereditary ataxia” diagnosis.
The hyperkinetic movements started in infancy and
her parents described her as a restless baby. When she
was examined, at age 34 and at follow-up at age 36, she
had obvious hyperkinetic movements, most prominent
in the trunk. She reported no obvious progression, but
Fig. 1 The clinical spectrum of Benign Hereditary Chorea
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worsening in the involuntary movements during adoles-
cence and pregnancy. She described her movements as a
lack of ability to keep her body at rest. She experienced her
first pneumonia at the age of 34 years and was diagnosed
with asthma at the age of 36 years and for which she re-
ceived medications.
The most noticeable findings at the first examination
were myoclonic movements in the trunk, unsteadiness
with abnormal gait and the inability to walk ten consecu-
tive steps in tandem. She was, however, able to stand with
her feet together. She had intermittent sway when sitting
and subtle choreic movements were observed in her hands.
Her SARA score was 6/40 points, with unsteadiness and
very mild ataxia in extremities. Her speech was normal.
After two years follow-up the examination was similar
with the same SARA score (6/40 points).
Elevated levels of thyroid-stimulating hormone in
serum (TSH), with normal thyroxin (free T4) values were
measured.
Genetics
All affected subjects carried a point mutation in exon 3,
c.671 T > G, p.Leu224Arg, previously reported for this
family [5]. Array CGH was normal in the index patient.
Fig. 2 The pedigree of the family
Table 2 Clinical data of the affected family members
SARA score Hyperkinetic
movementsa
Thyroidea Lungs MMS IQ Verbal IQ
(percentile)
Performance IQ
(percentile)
II:4 12.5 Dystonia Normal values,
treated earlier
Asthma NA NA
II:7 10.5 Dystonia, mild ataxia Hypothyreoses,
treated
Asthma NA NA
III:6 6 Myoclonus, mild
ataxia
Compensated
valuesb
Asthma 30/30 99 41th 59th
III:7 7 Dystonia Compensated
valuesb
Frequent
infections
NA NA
III:8 5 Dystonia, stuttering,
tics,
Normal values No lung
problems
NA NA
IV:1 5.5 Normal values Asthma 0/30 90 14th 95th
IV:2 5 Normal values Asthma 30/30 81 NA NA
IV:3 7 Compensated
valuesb
Asthma 30/30 86 30th 68th
aIn addition to chorea
bNormal fT4, but elevated TSH
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Conclusions
This family presented a broad spectrum of hyperkinetic
movements with chorea as the most prominent symp-
tom in the youngest generation, but with combinations
of dystonia, myoclonus, mild ataxia and stuttering in the
older generations. At the time of examination, all af-
fected subjects exhibited unsteadiness, and were unable
to walk in consecutive tandem steps. The affected index
family member was originally diagnosed with hereditary
ataxia, due to family history and mild ataxia. The pre-
dominant feature, chorea, was probably overseen in this
family and delayed the identification of the correct eti-
ology. In addition neither progression nor atrophy of the
cerebellum on MRI scans were observed in this family.
The diagnosis was therefore revised. This emphasizes
the importance of accurate phenomenology and the im-
portance of examination of more family members due to
intrafamiliar clinical heterogeneity, which is commonly
seen in monogenetic disorders, Table 1 [30].
Even though myoclonus, dystonia or chorea have been
reported in various genetic forms of hereditary ataxia,
mutation screening of the NKX2-1 gene (BHC) should
be made in cases of juvenile “ataxia” with no other cause
found. There is a wide phenotypic heterogeneity in BHC
families, in addition to frequent de novo mutations.
Conversely, BHC may share some clinical features with
other hyperkinetic disorders, especially where a mixture of
choreic movements, myoclonus and dystonia is concerned,
Table 1 [6, 9, 11, 18, 31]. An alternative diagnosis in this
family may have been myoclonic dystonia (DYT11), as
myoclonus and dystonia were additional movements in
generation II and III. The lack of maternal imprinting in
the pedigree and typical choreic movements in the youn-
gest generation made however the diagnosis unlikely [8].
In this family a diagnosis of hereditary ataxia was less
likely as the hyperkinetic feature chorea was the most
prominent symptom and finding, even though all subjects
were unsteady and two had mild ataxia. Hyperkinetic
movements, autosomal dominant inheritance pattern,
early onset, normal MRI scans and minimal progression
made us therefore consider BHC [6]. A correct diagnosis
is of great importance for the patients, especially as many
differential diagnoses, including early onset ataxia, often
have a more severe prognosis compared to BHC [30].
However, slight progression in children could be masked
by overall improved motor skills and can therefore be dif-
ficult to assess.
The opposite may also be true as there are some fam-
ilies with BHC phenotypes that do not have NKX2-1
mutations. Some families have been reported to have
ADCY5 mutations [18, 19]. The main distinctive features
that may help to differentiate the ADCY5 families from
NKX2-1 families are facial myokimias, paroxysmal
movement disorders, spasticity, more prominent dys-
tonic features and clinical progression in the ADCY5
families reported.
All affected members of the family reported concen-
tration problems and the neuropsychological domains
attention, working memory and processing speed were
indeed affected. The patients who were extensively cog-
nitively tested were consistently better in executive and
visuospatial functions as compared to verbal functions,
with verbal IQ being consistently lower than executive
performance IQ. Although previous reports on cognition
in BHC have been conflicting, it has still not been estab-
lished whether the impairment is a direct consequence
of the different mutations, whether it is biased by the
motor symptoms or as a consequence of hypothyroidism
in some of the subjects. A drawback in this and previous
reports is the low number of patients available for
neuropsychological testing.
Even though a broad specter of cognitive profiles are
reported in previous papers on BHC patients, the pheno-
type usually shows a mild cognitive decline and no alter-
ation over time has been reported. Normal cognitive
status is reported to be more likely in BHC compared to
other chorea genotypes, and is considered to be a good
clue to differentiate BHC from neurodegenerative forms
of chorea [31–33]. Our observations suggest that, even
when patients have some alterations in cognitive tests,
they have completely different cognitive profiles compared
to the hereditary neurodegenerative forms of chorea [6].
Fig. 3 A typical Archimedes spiral drawing by one of the
affected subjects
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To date, the most successful treatments reported in a
few individual patients with BHC are tetrabenazine and
levodopa [5, 20, 24]. These medications were tested in
some of the patients, but only side-effects and no or lit-
tle benefit on the hyperkinetic movements was observed.
Therefore no conclusions or guidelines can be drawn
from this family or previous reports.
The best treatment options for most patients with BHC
are probably still physical activity, physiotherapy, multidis-
ciplinary facilitation at school and at work, and yearly lung
and thyroid controls and treatment if needed.
In conclusion, although the neurological spectrum of
BHC is more and more delineated, our family illustrates
that hyperkinetic movement in addition to chorea can
be prominent in these families. Therefore, we suggest
considering BHC with mutations in the NKX2-1 gene in
the diagnostic workup also in those patients with hyper-
kinetic movements such as early onset dystonia and
ataxia.
Consent
Written informed consent was obtained from patients
for publication of this Case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Additional files
Additional file 1: Video 1. Video 1 illustrates choreic movements in
one of the patients. (MOV 6721 kb)
Additional file 2: Video 2. Video 2 illustrates chorea, dystonia and
hanging patellar reflex in one of the patients. (MOV 9599 kb)
Additional file 3: Video 3. Video 3 illustrated mild ataxia when
performing the heel–knee–shin test. (WMV 3646 kb)
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